A Phase I/II Study of Local Field Irradiation and Temozolomide Followed by Continuous Infusion Plerixafor as an Upfront Therapy for Newly Diagnosed Glioblastoma GBM

Trial Profile

A Phase I/II Study of Local Field Irradiation and Temozolomide Followed by Continuous Infusion Plerixafor as an Upfront Therapy for Newly Diagnosed Glioblastoma GBM

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 02 Aug 2017

At a glance

  • Drugs Plerixafor (Primary) ; Temozolomide
  • Indications Glioblastoma; Glioma
  • Focus Adverse reactions
  • Most Recent Events

    • 27 Jul 2017 Status changed from recruiting to active, no longer recruiting.
    • 02 Jun 2017 Results of association of SDF1 inhibition with relative cerebral blood volume of glioblastoma (n=28) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 07 Jun 2016 Preliminary results from Phase I part of this study (n=9) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top